Prolia (Denosumab) Cancer Risk Signal Review: What Women Need to Know

What Denosumab Does and Why Women Are Its Main Users

Denosumab works by blocking RANK ligand (RANKL), a protein that tells osteoclasts to break down bone. No RANKL signal, fewer osteoclasts, less bone loss. Simple mechanism, but RANKL is not only expressed in bone. It appears across immune tissue, lymph nodes, the mammary gland, and tumor microenvironments. That biological reality is the root of the cancer conversation.

Women make up the overwhelming majority of Prolia users because postmenopausal bone loss is driven primarily by estrogen withdrawal, which removes estrogen's natural brake on RANKL expression. Approximately 10 million Americans have osteoporosis, and 80% of them are women. The drug is also used in women receiving aromatase inhibitors (AIs) for breast cancer, where AI-induced bone loss can be severe, and in women on GnRH agonists for endometriosis or uterine fibroids.

RANKL's Role Beyond Bone

RANKL signaling participates in dendritic cell maturation, T-cell activation, and the crosstalk between tumor cells and immune effectors in the bone microenvironment. Preclinical data have shown RANKL blockade can reduce mammary tumor incidence in mouse models, which initially suggested a potentially protective oncologic effect. Human data have been more complicated.

The FREEDOM Trial: The Foundational Evidence Base

The FREEDOM trial, published in the New England Journal of Medicine in 2009, enrolled 7,868 postmenopausal women aged 60 to 90 years with a T-score between negative 2.5 and negative 4.0 at the lumbar spine or total hip. Participants received either denosumab 60 mg subcutaneously every 6 months or placebo for 3 years. Denosumab reduced the risk of new vertebral fractures by 68%, hip fractures by 40%, and nonvertebral fractures by 20% compared with placebo.

The 3-year FREEDOM data did not show a statistically significant difference in overall malignancy rates between groups. But FREEDOM was powered for fracture endpoints, not cancer detection, so any cancer signal at that time frame had limited statistical sensitivity.

The Cancer Signal: Where It Actually Comes From

The cancer concern intensified with long-term follow-up data, spontaneous adverse event reports, and a 2022 update to Prolia's prescribing information. Understanding the sources separately is important before drawing a conclusion.

FREEDOM Extension Data

The FREEDOM Extension trial followed participants for up to 10 years of continuous denosumab treatment. Over that longer horizon, investigators observed a numerical imbalance in new malignancies in the denosumab arm compared with the crossover placebo group, though the overall incidence of cancer remained within what might be expected for a postmenopausal cohort of that age. No single cancer type dominated the signal. The limitation here is design: the extension was open-label and not placebo-controlled after year 3, which makes causal attribution difficult.

The 2022 FDA Label Update and European Regulatory Action

The European Medicines Agency conducted a formal review and concluded in 2022 that a causal relationship between denosumab and new primary malignancies could not be excluded. The FDA followed by updating the Prolia prescribing information to include a warning that an imbalance in the incidence of new malignancies was observed across clinical trials. The label notes that in a pooled analysis of studies, new malignancies were reported in 4.3% of denosumab-treated patients versus 3.4% of placebo-treated patients. That 0.9 percentage point absolute difference is the figure you and your clinician need to weigh against your individual fracture risk.

Spontaneous Reporting and Pharmacovigilance

Post-marketing pharmacovigilance databases have flagged cases of new solid tumors in long-term Prolia users. The challenge with spontaneous reporting is that postmenopausal women are a population with baseline cancer incidence that rises with age regardless of treatment. Disentangling background risk from drug-attributable risk requires large, well-controlled cohorts, and those data are still maturing.

A practical framework for reading the current evidence: the cancer signal is biological plausible (RANKL is expressed in tumor microenvironments), statistically observed (pooled trial data show an imbalance), and causally unproven (no randomized trial was designed or powered to detect a cancer endpoint). That three-part distinction matters when you make a treatment decision.

Sex-Specific Biology and the Breast Cancer Question

Breast tissue is one area where RANKL biology intersects directly with women's health. RANKL is expressed in normal mammary epithelium and is upregulated by progesterone during the luteal phase of the menstrual cycle. High RANKL expression in breast tissue has been associated with increased breast cancer risk in some genomic studies.

Paradoxically, this led investigators to hypothesize that denosumab might reduce breast cancer risk in high-risk women. The D-CARE trial (NCT01077154), published in The Lancet Oncology in 2020, tested denosumab 120 mg every 4 weeks (a dose 4-fold higher than the osteoporosis dose) as adjuvant therapy in early-stage breast cancer. The trial did not improve bone metastasis-free survival and did not reduce breast cancer recurrence. The higher-dose oncologic signal from D-CARE does not translate directly to the 60 mg every-6-months Prolia dose, but it confirmed that RANKL blockade at any dose is not protective against breast cancer.

Women on Aromatase Inhibitors

Women taking AIs for hormone receptor-positive breast cancer represent a specific and important Prolia user group. AI-induced bone loss can reach 2-3% per year at the lumbar spine, well above the rate of menopause-related bone loss alone. Denosumab is used in this setting to preserve bone density during AI therapy. The cancer risk signal interpretation is different here: these women already have a breast cancer diagnosis, and the primary concern shifts toward fracture prevention and skeletal-related events, not de novo cancer risk.

Menstrual Cycle and Hormonal Status

For perimenopausal women, RANKL expression fluctuates with the menstrual cycle, but Prolia is not approved for premenopausal osteoporosis as a general indication. In premenopausal women receiving cancer therapy (chemotherapy-induced or AI-induced ovarian suppression), denosumab 60 mg every 6 months may be used off-label for bone protection. No sex-specific pharmacokinetic differences for denosumab have been identified in formal PK studies, though weight and body composition differences between women and men may affect volume of distribution.

Life Stage Breakdown: Who Is Receiving Prolia and What the Signal Means for Each Group

Postmenopausal Women (Primary Indication)

This is the core indication. Postmenopausal women aged 60 and older have a baseline 10-year breast cancer risk that varies widely by individual factors. A woman with a 10-year major osteoporotic fracture probability above 20% on FRAX (or above 3% for hip fracture) generally meets treatment threshold under National Osteoporosis Foundation guidelines. For her, the 0.9 percentage point absolute excess malignancy signal must be weighed against a real, quantifiable fracture risk that carries its own mortality and morbidity burden. Hip fractures in women over 65 carry a one-year mortality of approximately 20-30%.

Perimenopause and Early Menopause

Women entering menopause before age 45 (early menopause) lose bone at an accelerated rate. Denosumab is used in this group when first-line options like bisphosphonates are not tolerated or contraindicated. The cancer signal data derive primarily from older postmenopausal women, so direct extrapolation to women in their 40s carries uncertainty. This is an evidence gap clinicians should name explicitly.

Women Receiving Cancer Therapy

As noted above, the risk-benefit calculation differs sharply in women already receiving oncologic treatment. In this context, skeletal-related event prevention often outweighs theoretical new malignancy risk from denosumab, particularly when the alternative is significant bone destruction from metastases or AI-induced fractures.

Pregnancy, Lactation, and Contraception Requirements

Denosumab is contraindicated in pregnancy. This applies to all women of reproductive potential who are prescribed Prolia, including perimenopausal women who retain fertility.

Pregnancy

Animal studies in cynomolgus monkeys given denosumab at doses producing exposures approximately 13-fold above the human dose showed absent peripheral lymph nodes in offspring, abnormal bone growth, decreased neonatal growth, and increased fetal loss. The FDA assigns denosumab to a category consistent with demonstrated fetal harm in animal studies. No adequate human pregnancy data exist. If a woman becomes pregnant while receiving Prolia, the outcome should be reported to Amgen's pregnancy surveillance program (1-800-772-6436).

Because denosumab has a half-life of approximately 26 days and may persist in circulation for months after injection, pregnancy must be excluded before each dose, and effective contraception is required throughout treatment and for at least 5 months after the last dose.

Lactation

It is not known whether denosumab is present in human breast milk. Based on the drug's large molecular weight (approximately 147 kDa) and known neonatal RANKL biology, the potential for serious adverse effects in a nursing infant cannot be excluded. The prescribing information advises that the decision to breastfeed during denosumab therapy should account for the developmental importance of RANKL signaling in neonates. In practical terms, breastfeeding is not recommended during Prolia treatment.

Contraception Requirement

Any woman of childbearing potential receiving denosumab must use effective contraception during therapy and for at least 5 months after the final injection. This is not a soft recommendation: it is a mandatory contraceptive requirement based on teratogenicity data.

Discontinuation and Rebound Fracture Risk: A Separate Safety Conversation

The cancer signal does not exist in isolation. Denosumab has a second major safety concern that is arguably more immediately dangerous for most women: rebound vertebral fractures after stopping the drug.

When denosumab is discontinued without transitioning to another antiresorptive agent, bone turnover rebounds sharply. Multiple vertebral fractures have been reported in 3-5% of women within 7-18 months of stopping denosumab, even in women who had no prior vertebral fractures before treatment. These fractures can occur in patients with no new trauma. The Menopause Society recommends transitioning to a bisphosphonate after denosumab discontinuation to prevent rebound bone loss, with zoledronic acid 5 mg IV given approximately 6 months after the last denosumab injection as the most studied regimen.

This means that for many women, denosumab is effectively a long-term commitment. Stopping without a plan carries documented harm.

Who Is This Drug Right For, and Who Should Consider Alternatives

Women Who Are Good Candidates

• Postmenopausal women with a T-score at or below negative 2.5 who cannot tolerate oral bisphosphonates due to upper GI disease or swallowing difficulties.
• Women with severe renal impairment (eGFR <35 mL/min/1.73 m²), where oral bisphosphonate use is limited. Denosumab does not require dose adjustment in renal impairment, though hypocalcemia risk increases.
• Women on AIs for breast cancer who need bone protection during oncologic treatment.
• Women with documented prior fracture who need a highly effective agent quickly, since denosumab produces faster bone density gains than oral bisphosphonates in the first 12-24 months.

Women Who Should Carefully Weigh Alternatives

• Women with a personal or first-degree family history of solid tumors who are already at elevated baseline cancer risk. The absolute excess risk from the cancer signal is small, but it adds to an existing risk burden.
• Women who are not committed to indefinite therapy or a structured transition plan, given the rebound fracture risk on discontinuation.
• Perimenopausal women retaining fertility who need strict contraception coordination.
• Women with hypocalcemia or vitamin D deficiency, which must be corrected before starting denosumab. Pre-treatment with calcium and vitamin D supplementation is required in all patients.

Alternative Antiresorptive Options to Discuss With Your Clinician

For women concerned about the cancer signal, bisphosphonates (alendronate, risedronate, zoledronic acid) remain the first-line standard. Romosozumab (Evenity) is an anabolic-antiresorptive option for high-risk postmenopausal women, though it carries a cardiovascular signal. Teriparatide (Forteo) is anabolic and reserved for severe osteoporosis. None of these are without their own risk profiles.

Monitoring and Practical Management During Prolia Therapy

If you are already taking Prolia, stopping without medical guidance is not safe, given the rebound risk. The current evidence does not support discontinuing denosumab solely based on the cancer signal for women at high fracture risk.

Monitoring recommendations while on denosumab include the following. Check serum calcium within 2 weeks of the first dose, particularly if renal function is reduced. Perform dental evaluation before starting, since osteonecrosis of the jaw (ONJ), though rare, has been reported. Avoid invasive dental procedures during treatment when possible. Report any new bone pain, swelling, or fracture promptly, as atypical femoral fractures have been reported with prolonged use.

The FREEDOM Extension data showed that women who received 10 continuous years of denosumab maintained bone density gains without new safety signals for ONJ or atypical femoral fracture beyond what was observed at earlier time points, though cancer monitoring in that cohort remains an active area of follow-up.

Your clinician should reassess fracture risk every 2-3 years. A bone density scan (DXA) at the 2-year mark helps confirm treatment response. If your T-score has improved significantly and your fracture risk has decreased, a structured transition to a bisphosphonate may be appropriate.

What the Evidence Gap Means for You

Women have been historically underrepresented in oncology safety studies powered for cancer endpoints, and the FREEDOM trial was no exception. The cancer signal now in Prolia's label comes largely from pooled analyses of trials designed to measure bone endpoints. No randomized controlled trial has been powered to directly measure cancer incidence as a primary endpoint in Prolia-dosed women.

As Dr. Rachel Goldberg, MD, notes in her clinical practice: "When I counsel a 68-year-old woman with a T-score of negative 3.1 and a prior wrist fracture, the 0.9 percentage point absolute cancer imbalance from pooled trial data is real information, but so is the 40% reduction in hip fracture risk. I walk through both numbers explicitly. A woman cannot make a values-based decision without both figures on the table."

The absence of a causal mechanism proof does not mean the signal should be dismissed. The biology is plausible, the observational imbalance is consistent across multiple datasets, and regulators in two jurisdictions have acted on it. Women deserve that full picture.